In high-risk patients, the use of other procedures, such as transjugular renal biopsy or laparoscopic kidney biopsy, also may decrease hemorrhagic complications.27, 28, 29 A possible limitation of the study is the single-center design, which could decrease the generalizability of our results and their external validity. Desmopressin acetate (DDAVP), a selective agonist of type 2 vasopressin receptors, is sometimes used prior to percutaneous renal biopsy to reduce the risk of bleeding complications. Manno C(1), Bonifati C, Torres DD, Campobasso N, Schena FP. Author information: (1)Nephrology, Dialysis and Transplant Unit, Department of Emergency and Organ Transplantation, University of Bari, Piazza Giulio Cesare 11, Bari, Italy. c.manno@nephro.uniba.it Original Investigation Desmopressin Acetate in Percutaneous Ultrasound-Guided Kidney Biopsy: A Randomized Controlled Trial Carlo Manno, MD, Carmen Bonifati, MD, Diletta Domenica Torres, MD, Desmopressin administered prior to percutaneous kidney biopsy decreases the risk of bleeding and hematoma size from the procedure, according to researchers. Background. Desmopressin acetate, also known as DDAVP (1-deamino-8-d-arginine vasopressin), a selective agonist of type 2 vasopressin receptors, is sometimes used prior to percutaneous renal biopsy to reduce the risk of bleeding complications [1–4]. Abstract. Desmopressin acetate (DDAVP), a selective agonist of type 2 vasopressin receptors, is sometimes used prior to percutaneous renal biopsy to reduce the risk of bleeding complications. Medscape - Indication-specific dosing for DDAVP, Stimate (desmopressin), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information. 1-deamino 8-d-arginine Vasopressin (DDAVP) in Percutaneous Ultrasound-guided Renal Biopsy The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Percutaneous renal biopsy protocol Department of Nephrology, St George Hospital, Kogarah Revised Jan 2015 A. Pre Procedure 1. Ensure the patient has ceased anticoagulants/ antiplatelet agents and NSAIDS for 7 days (ideally 14.